
STAT+: Doudna talks cost, access issues looming over first CRISPR therapy
“How do we make sure that a technology like CRISPR — you know, no offense intended — is not just going to make a few people rich, but it’s going… […]
“How do we make sure that a technology like CRISPR — you know, no offense intended — is not just going to make a few people rich, but it’s going… […]
Realizing the benefits of animals with intentional genomic alterations depends on gaining consumers’ trust, which in turn requires a regulatory system that consumers can count on. […]
A new Bay Area biotech is harnessing artificial intelligence to better understand and predict RNA structures in hopes of developing new therapeutics. […]
“The industry is learning that almost unlimited access to capital, chasing testing volume and adding cost on the back end, is not sustainable,” said Invitae CEO Ken Knight. […]
Element’s machine can now read a whole human genome for as little as $200 — the cost of a couple trips to the grocery store. […]
Pacific Biosciences, best known for its niche approach to DNA sequencing, announced plans to launch a product that will put the company in direct competition with Illumina. […]
Copyright © 2023 Biotech Networks, LLC